PreciseDx AI-enabled digital pathology detects Parkinson’s disease
June 2022—PreciseDx announced its AI-enabled digital pathology technology can accurately diagnose Parkinson’s disease in patients prior to severe onset of symptoms.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
CE-marked Nova Max Pro creatinine/eGFR meter launched in EU
June 2022—Nova Biomedical launched the CE-marked Nova Max Pro creatinine/eGFR meter system in the EU market. Nova Max Pro is designed to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The meter and creatinine biosensor measure blood creatinine and calculate estimated glomerular filtration rate from a 1.2-μL capillary fingerstick blood sample in 30 seconds. The measuring technology is based on the Nova StatSensor Creatinine technology.
Seegene RV assay gets CE-IVD mark, Australian TGA approval
June 2022—Seegene announced that its Allplex RV Master Assay has achieved CE-IVD marking and received approval from Australia’s Therapeutic Goods Administration.
Versant Dx announces strategy to accelerate use of digital pathology
June 2022—Versant Diagnostics has announced a strategy in which the company will focus on anatomic pathology, precision medicine, and the digital transformation of the industry. The company said it is positioning itself to become the nation’s largest independent physician services company through the acquisition of independent pathology practices, and it will provide capital for practices to convert to digital pathology while maintaining physician leadership.
Paragon Genomics unveils CleanPlex Emerging Variant Add-on V2
April 2022—Paragon Genomics announced the release of its Emerging Variant Add-on V2. The panel is designed to be used with existing CleanPlex SARS-CoV-2 products, the company says, to maintain high coverage for variant calling and identification as the virus evolves. It includes added primers for enhanced coverage of critical variants, such as alpha, beta, delta, mu, and omicron, and has been confirmed in silico to cover the defining and characteristic mutations of the omicron sublineages, BA.1, BA.2, and BA.3.
Thermo Fisher RT-LAMP tests for ID surveillance
April 2022—Thermo Fisher Scientific has launched two reverse transcription loop-mediated isothermal amplification (RT-LAMP)–based solutions for research use only. The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2, is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal, or nasopharyngeal swab samples. The kit includes two protocols, one for crude sample types with a 30-minute turnaround time and one for increased sensitivity with purified RNA sample types that has a one-hour turnaround time.
Opdivo + chemo approved as neoadjuvant treatment for NSCLC
April 2022—The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting. The treatment is approved regardless of PD-L1 status and is based on the CheckMate -816 trial, the first positive phase three trial of an immunotherapy-based combination used before surgery for resectable NSCLC.
Beckman Coulter Life Sciences, AmoyDx ink agreement
April 2022—Beckman Coulter Life Sciences has entered into an agreement with AmoyDx to develop applications on the Biomek NGenius liquid handling system. The Biomek NGenius system is scheduled to launch in the second quarter of this year; it is not intended or validated for use in diagnosis of disease or other conditions.
Roche launches Avenio Edge System
April 2022—Roche launched its Avenio Edge System, an all-in-one preanalytical platform that is designed to minimize manual touchpoints and includes ready-to-load reagents, validated protocols, onboard capabilities, and intuitive software to manage next-generation sequencing sample workflows.
Roche launches Cobas Pulse system
April 2022—Roche announced the launch of the Cobas Pulse system, the company’s newest generation of connected POC solutions for professional blood glucose management, in select countries accepting the CE mark.